Jim Simons Stock Portfolio: 5 Biggest Healthcare Stocks

In this piece, we will take a look at the five biggest healthcare stocks in Jim Simons’ stock portfolio. If you want to learn more about the billionaire hedge fund boss and some recent developments in the healthcare industry, then check out Jim Simons Stock Portfolio: 12 Biggest Healthcare Stocks.

5. Biogen Inc. (NASDAQ:BIIB)

Renaissance Technologies’ Q2 2023 Investment: $316 million

Biogen Inc. (NASDAQ:BIIB) is a pharmaceutical firm that focuses its efforts on developing treatments for nervous system disorders and diseases. It has done remarkably well on the financial front as of late, by having beaten analyst EPS estimates in all four of its latest quarters. Analysts have also priced in a whopping $99 upside over the current share price through an average share price target of $330.

By Q2 2023 end, 64 among the 910 hedge funds tracked by Insider Monkey were Biogen Inc. (NASDAQ:BIIB)’s shareholders. Jim Simons’ Renaissance Technologies owns the largest stake among these which is worth $316 million and comes via 1.1 million shares.

4. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Renaissance Technologies’ Q2 2023 Investment: $447 million

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is a biotechnology firm developing treatments for cystic fibrosis. The shares are rated Buy on average and analysts have set an average share price target of $388.67.

For their second quarter of 2023 investments, 54 out of the 910 hedge funds polled by Insider Monkey had bought the firm’s shareholders. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)’s biggest hedge fund shareholder is Jim Simons’ Renaissance Technologies as it owns $447 million worth of shares.

3. United Therapeutics Corporation (NASDAQ:UTHR)

Renaissance Technologies’ Q2 2023 Investment: $482 million

United Therapeutics Corporation (NASDAQ:UTHR) is a small biotechnology company developing treatments for several ailments such as complications resulting from exercise. The firm scored a win in late October 2023 when it announced that it had enrolled the first patient in its trial for a drug targeting lung fibrosis.

As of June 2023 end, 45 among the 910 hedge funds tracked by Insider Monkey had invested in United Therapeutics Corporation (NASDAQ:UTHR). Kurt Von Emster’s VenBio Select Advisor owns the largest stake among these which is worth $642 million.

2. Gilead Sciences, Inc. (NASDAQ:GILD)

Renaissance Technologies’ Q2 2023 Investment: $599 million

Gilead Sciences, Inc. (NASDAQ:GILD) is an American healthcare company whose treatments target a variety of ailments such as high blood pressure and hepatitis. Despite the fact that it beat analyst estimates for drug sales during the third quarter, its shares dropped post earnings as investors speculated that the beat was driven by unpredictable hospitalizations.

During this year’s second quarter, out of the 910 hedge funds part of Insider Monkey’s database, 56 were the firm’s investors. Gilead Sciences, Inc. (NASDAQ:GILD)’s biggest hedge fund shareholder is Peter Rathjens, Bruce Clarke, and John Campbell’s Arrowstreet Capital as it owns 8.8 million shares that are worth $684 million.

1. Novo Nordisk A/S (NYSE:NVO)

Renaissance Technologies’ Q2 2023 Investment: $1.5 billion

Novo Nordisk A/S (NYSE:NVO) is one of the largest pharmaceutical companies in the world. It’s also one of the best rated stocks on our list, as analysts have rated the shares as Strong Buy on average and set an average share price target of $101.76.

During Q2 2023, 43 hedge funds out of the 910 tracked by Insider Monkey had held a stake in Novo Nordisk A/S (NYSE:NVO). Jim Simons’ Renaissance Technologies owns the largest stake among these which is worth $1.5 billion.

Disclosure: None. You can also take a look at 14 Best Cyclical Stocks To Invest In and 10 Travel Stocks Billionaires Are Loading Up On.

Follow Insider Monkey on Twitter